Clinical Trials Browser

Phase 2 × Pancreatic Neoplasms × Nivolumab × Clear all

NCT03785210 2026-02-23

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Phase 2 Terminated

22 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03104439 2026-01-12

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07226856 2025-12-22

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02451982 2025-12-03

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06941857 2025-12-03

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Pancreatic Neoplasms

NCT03563248 2025-10-01

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03697564 2025-08-06

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

Phase 2 Completed

2 enrolled 10 charts

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03250273 2025-05-28

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Phase 2 Completed

44 enrolled 19 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms, Cholangiocarcinoma

NCT03161379 2025-02-03

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

Phase 2 Completed

31 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03190265 2024-08-07

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

Phase 2 Completed

61 enrolled 11 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Neoplasms, Pancreatic Neoplasms

NCT05116917 2024-05-28

INFLUENCE

Phase 2 Terminated

Gastrointestinal

Influenza, Human, Pancreatic Neoplasms

NCT05435053 2023-09-15

CHECKPOINT

Phase 2 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT04953962 2023-08-15

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT04212026 2023-07-18

Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.

Phase 2 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT04361162 2022-09-08

Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT04258150 2022-03-31

TRIPPLE-R

Phase 2 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT04377048 2020-05-06

Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

Phase 2 Unknown

Gastrointestinal

Pancreatic Neoplasms